Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Izawa

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Targeted Oncology|April 15, 2023
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 8, 2023
Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 studyDaisuke Takahari, Hitoshi Katai, Atsuo Takashima, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Targeted Oncology|May 6, 2023
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G TrialNaoki Izawa, Toshiki Masuishi, Naoki Takahashi, et al.
No to Shinkei = Brain and Nerve|June 14, 2005
[Significance of shunt efficacy decision of SPECT on idiopathic normal pressure hydrocephalus]Totaro Takeuchi, Tetsuya Ishihara, Hitoshi Kubo, et al.
Esophagus : Official Journal of the Japan Esophageal Society|November 25, 2025
Feasibility of endoscopic response evaluation after induction chemotherapy for determining treatment strategies in esophageal cancer: a post hoc analysis of the CROC trialChikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
International Journal of Radiation Oncology, Biology, Physics|July 5, 2024
Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical TrialChikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
The Oncologist|February 18, 2026
Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: A secondary analysis of a randomized clinical trialTakahiro Higashibata, Takaomi Kessoku, Shinya Kajiura, et al.
Cancer Science|October 19, 2020
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancerHiroko Hasegawa, Hiroya Taniguchi, Yoshiaki Nakamura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialJun Hamano, Takahiro Higashibata, Takaomi Kessoku, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Targeted Oncology|April 15, 2023
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 8, 2023
Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 studyDaisuke Takahari, Hitoshi Katai, Atsuo Takashima, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Targeted Oncology|May 6, 2023
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G TrialNaoki Izawa, Toshiki Masuishi, Naoki Takahashi, et al.
No to Shinkei = Brain and Nerve|June 14, 2005
[Significance of shunt efficacy decision of SPECT on idiopathic normal pressure hydrocephalus]Totaro Takeuchi, Tetsuya Ishihara, Hitoshi Kubo, et al.
Esophagus : Official Journal of the Japan Esophageal Society|November 25, 2025
Feasibility of endoscopic response evaluation after induction chemotherapy for determining treatment strategies in esophageal cancer: a post hoc analysis of the CROC trialChikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
International Journal of Radiation Oncology, Biology, Physics|July 5, 2024
Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical TrialChikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
The Oncologist|February 18, 2026
Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: A secondary analysis of a randomized clinical trialTakahiro Higashibata, Takaomi Kessoku, Shinya Kajiura, et al.
Cancer Science|October 19, 2020
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancerHiroko Hasegawa, Hiroya Taniguchi, Yoshiaki Nakamura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialJun Hamano, Takahiro Higashibata, Takaomi Kessoku, et al.
Pageof 7